• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Prenatal exposure to antipsychotic medications not associated with increased risk of neurodevelopmental disorders in offspring

byYuchen DaiandMichael Pratte
March 30, 2022
in Obstetrics, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Prenatal exposure to commonly prescribed antipsychotic medications did not appear to meaningfully increase risk of neurodevelopmental disorders in offspring.

2. The potential risk of neurodevelopmental disorder associated with aripiprazole requires further validation before causality can be assumed.

Evidence Rating Level: 2 (Good)

Study Rundown: Preclinical studies in animal models have demonstrated the neurocognitive sequelae of prenatal exposure to antipsychotic medications, however, its effect in humans during pregnancy has not been well described. This large-scale epidemiologic study nested in nationwide public and private health care utilization databases evaluated the association between in utero exposure to antipsychotic drugs and neurodevelopmental disorders (NDDs) in children. The main outcomes included autism spectrum disorder, attention-deficit/hyperactivity disorder, learning disability, speech or language disorder, developmental coordination disorder, intellectual disability, behavioral disorder, and the composite outcome of any NDD. Among 3.4 million children with up to 14 years of follow-up, commonly prescribed antipsychotic medications did not appear to meaningfully increase NDD risk in offspring, with the possible exception of exposure to aripiprazole. Although the benefits of antipsychotic treatment for pregnant women with severe mental illness are clear, close monitoring of neurodevelopment in offspring is recommended to ensure early intervention and support. A limitation of this study was that antipsychotic drug exposure was based solely on prescription status in the databases and not on clinical evidence of exposure leading to potential misclassification and confounding in the exposure group.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011

In-Depth [prospective cohort]: This birth cohort study included data from publicly (MAX, 2000-2014) and privately insured (MarketScan, 2003-2015) mother-child dyads, assessed for risks of NDD after prenatal exposure to any antipsychotic drug during the second half of pregnancy. The MAX cohort consisted of 2 034 883 unexposed and 9551 exposed pregnancies to antipsychotic medications (mean [SD] age, 26.8 [6.1] years). The MarketScan cohort consisted of 1 306 408 unexposed and 1221 exposed pregnancies (mean [SD] age, 33.1 [5.0] years). Hazard ratios (HRs) were estimated using Cox proportional hazards regression and combined through meta-analysis. After adjusting for confounding factors, risks were not meaningfully increased for exposure-outcome contrasts (eg, pooled unadjusted vs adjusted HRs [95%CI] for any NDD after any antipsychotic exposure: 1.91 [1.79-2.03] vs 1.08 [1.01-1.17]), with the possible exception of aripiprazole (1.36 [1.14-1.63]).

RELATED REPORTS

Adjuvant antipsychotic use in children treated for depression may be associated with movement disorders

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

Anti-psychotic medication use during pregnancy not associated with attention-deficit/hyperactivity disorder, autism spectrum disorder or small for gestational age in children

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Antipsychoticantipsychotic medicationsantipsychoticsteratogens
Previous Post

Cessation of aspirin in older adults not associated with adverse health effects

Next Post

Single-dose Ad26.COV2.S reduces risk of COVID-related hospitalization and death in South African healthcare workers

RelatedReports

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Pediatrics

Adjuvant antipsychotic use in children treated for depression may be associated with movement disorders

April 21, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

March 15, 2022
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Obstetrics

Anti-psychotic medication use during pregnancy not associated with attention-deficit/hyperactivity disorder, autism spectrum disorder or small for gestational age in children

August 23, 2021
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Obstetrics

Usage of first-line antidepressant medications in early pregnancy associated with selected birth defects

August 10, 2020
Next Post
Influenza vaccine not associated with increased risk of epilepsy in children

Single-dose Ad26.COV2.S reduces risk of COVID-related hospitalization and death in South African healthcare workers

#VisualAbstract: Cardiosphere-derived cell therapy slows disease progression in Duchenne muscular dystrophy

#VisualAbstract: Cardiosphere-derived cell therapy slows disease progression in Duchenne muscular dystrophy

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Wellness Check: Nutrition

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.